AstraZeneca lifts 2024 outlook
While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
Hosted on MSN2d
AstraZeneca Expands U.S. Investment PlanAstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...
British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that led to the detention ...
AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total ...
AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...
Pharmaceutical giant AstraZeneca said that the head of its China operations had been detained, after reports the firm was ...
Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
RSV symptoms include cough, fever, running nose, irritability, reduced activity, and pauses in breathing. Severe cases can ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback